questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-Serine-Threonine Kinases
Mitogen-Activated Protein Kinases
Extracellular Signal-Regulated MAP Kinases
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 3 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Mitogen-Activated Protein Kinase 3 : Questions médicales les plus fréquentes",
"headline": "Mitogen-Activated Protein Kinase 3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Mitogen-Activated Protein Kinase 3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-24",
"dateModified": "2025-02-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase 3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Extracellular Signal-Regulated MAP Kinases",
"url": "https://questionsmedicales.fr/mesh/D048049",
"about": {
"@type": "MedicalCondition",
"name": "Extracellular Signal-Regulated MAP Kinases",
"code": {
"@type": "MedicalCode",
"code": "D048049",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.567.249"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase 3",
"alternateName": "Mitogen-Activated Protein Kinase 3",
"code": {
"@type": "MedicalCode",
"code": "D048052",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Juan Wang",
"url": "https://questionsmedicales.fr/author/Juan%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Division of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Republic of Korea."
}
},
{
"@type": "Person",
"name": "Mohammad Shafiq",
"url": "https://questionsmedicales.fr/author/Mohammad%20Shafiq",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Kumaravelu Jagavelu",
"url": "https://questionsmedicales.fr/author/Kumaravelu%20Jagavelu",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Neeraj Kumar Verma",
"url": "https://questionsmedicales.fr/author/Neeraj%20Kumar%20Verma",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Jimut Kanti Ghosh",
"url": "https://questionsmedicales.fr/author/Jimut%20Kanti%20Ghosh",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Incident commander decision making: Quantitative evaluation of instantaneous and considered decisions.",
"datePublished": "2023-09-23",
"url": "https://questionsmedicales.fr/article/37748355",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.apergo.2023.104139"
}
},
{
"@type": "ScholarlyArticle",
"name": "Understanding the processes behind the decisions - GPs and complex multimorbidity decision making.",
"datePublished": "2022-06-28",
"url": "https://questionsmedicales.fr/article/35761167",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12875-022-01781-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "For which decisions is Shared Decision Making considered appropriate? - A systematic review.",
"datePublished": "2022-09-28",
"url": "https://questionsmedicales.fr/article/36220675",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pec.2022.09.015"
}
},
{
"@type": "ScholarlyArticle",
"name": "A theory of oral healthcare decision-making in Appalachia.",
"datePublished": "2024-05-20",
"url": "https://questionsmedicales.fr/article/38768179",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0303831"
}
},
{
"@type": "ScholarlyArticle",
"name": "Confidence and risky decision-making in gambling disorder.",
"datePublished": "2023-08-21",
"url": "https://questionsmedicales.fr/article/37603457",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1556/2006.2023.00041"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-Serine-Threonine Kinases",
"item": "https://questionsmedicales.fr/mesh/D017346"
},
{
"@type": "ListItem",
"position": 6,
"name": "Mitogen-Activated Protein Kinases",
"item": "https://questionsmedicales.fr/mesh/D020928"
},
{
"@type": "ListItem",
"position": 7,
"name": "Extracellular Signal-Regulated MAP Kinases",
"item": "https://questionsmedicales.fr/mesh/D048049"
},
{
"@type": "ListItem",
"position": 8,
"name": "Mitogen-Activated Protein Kinase 3",
"item": "https://questionsmedicales.fr/mesh/D048052"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Mitogen-Activated Protein Kinase 3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Mitogen-Activated Protein Kinase 3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Mitogen-Activated Protein Kinase 3",
"description": "Comment diagnostiquer une dysfonction de MAPK3 ?\nQuels tests sont utilisés pour évaluer MAPK3 ?\nY a-t-il des biomarqueurs associés à MAPK3 ?\nMAPK3 est-elle impliquée dans des maladies spécifiques ?\nQuels symptômes peuvent indiquer un problème avec MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Decision+Making&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Mitogen-Activated Protein Kinase 3",
"description": "Quels symptômes sont liés à une activation excessive de MAPK3 ?\nMAPK3 affecte-t-elle le système immunitaire ?\nQuels signes cliniques sont associés à MAPK3 ?\nY a-t-il des symptômes neurologiques liés à MAPK3 ?\nComment la MAPK3 influence-t-elle le stress cellulaire ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Decision+Making&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Mitogen-Activated Protein Kinase 3",
"description": "Comment prévenir les dysfonctionnements de MAPK3 ?\nY a-t-il des habitudes à éviter pour MAPK3 ?\nLe stress peut-il affecter MAPK3 ?\nDes exercices spécifiques aident-ils MAPK3 ?\nLa gestion du poids influence-t-elle MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Decision+Making&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Mitogen-Activated Protein Kinase 3",
"description": "Quels traitements ciblent MAPK3 ?\nLa thérapie génique peut-elle corriger MAPK3 ?\nQuels médicaments affectent la voie MAPK3 ?\nY a-t-il des traitements naturels pour MAPK3 ?\nComment la nutrition influence-t-elle MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Decision+Making&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Mitogen-Activated Protein Kinase 3",
"description": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?\nMAPK3 est-elle liée à des maladies auto-immunes ?\nComment MAPK3 affecte-t-elle le cancer ?\nY a-t-il des risques cardiovasculaires liés à MAPK3 ?\nMAPK3 peut-elle influencer le vieillissement ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Decision+Making&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Mitogen-Activated Protein Kinase 3",
"description": "Quels facteurs de risque sont associés à MAPK3 ?\nL'âge influence-t-il l'activité de MAPK3 ?\nY a-t-il des prédispositions génétiques pour MAPK3 ?\nLe mode de vie influence-t-il MAPK3 ?\nDes infections peuvent-elles affecter MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Decision+Making&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction de MAPK3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer MAPK3 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de phosphorylation et les analyses protéomiques sont courants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à MAPK3 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de certaines protéines peuvent indiquer une dysfonction de MAPK3."
}
},
{
"@type": "Question",
"name": "MAPK3 est-elle impliquée dans des maladies spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est liée à des cancers et des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec MAPK3 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés selon la maladie, comme la fatigue ou des douleurs chroniques."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une activation excessive de MAPK3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation excessive peut entraîner une inflammation et des douleurs."
}
},
{
"@type": "Question",
"name": "MAPK3 affecte-t-elle le système immunitaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle joue un rôle dans la régulation de la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à MAPK3 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des éruptions cutanées ou des troubles métaboliques peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques liés à MAPK3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques peuvent survenir en cas de dysfonction de MAPK3."
}
},
{
"@type": "Question",
"name": "Comment la MAPK3 influence-t-elle le stress cellulaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle régule les réponses au stress, affectant la survie cellulaire et l'apoptose."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dysfonctionnements de MAPK3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une bonne nutrition et de l'exercice, est recommandé."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter pour MAPK3 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et une alimentation riche en graisses saturées est conseillé."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter MAPK3 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber la signalisation de MAPK3."
}
},
{
"@type": "Question",
"name": "Des exercices spécifiques aident-ils MAPK3 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des exercices réguliers peuvent améliorer la régulation de MAPK3."
}
},
{
"@type": "Question",
"name": "La gestion du poids influence-t-elle MAPK3 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un poids santé peut aider à réguler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent MAPK3 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques de MAPK3 sont en développement pour traiter certains cancers."
}
},
{
"@type": "Question",
"name": "La thérapie génique peut-elle corriger MAPK3 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est une approche potentielle pour corriger des mutations de MAPK3."
}
},
{
"@type": "Question",
"name": "Quels médicaments affectent la voie MAPK3 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les inhibiteurs de MEK peuvent moduler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour MAPK3 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales peuvent influencer la signalisation de MAPK3."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle MAPK3 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut moduler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme le cancer, l'inflammation chronique et des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "MAPK3 est-elle liée à des maladies auto-immunes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans MAPK3 peuvent contribuer à des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Comment MAPK3 affecte-t-elle le cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation aberrante de MAPK3 est souvent observée dans divers types de cancer."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques cardiovasculaires liés à MAPK3 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien entre MAPK3 et des maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "MAPK3 peut-elle influencer le vieillissement ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dysfonctionnements de MAPK3 sont associés à des processus de vieillissement prématuré."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à MAPK3 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'obésité, le tabagisme et le stress sont des risques connus."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il l'activité de MAPK3 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activité de MAPK3 peut diminuer avec l'âge, affectant la signalisation cellulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques pour MAPK3 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mutations génétiques peuvent prédisposer à des dysfonctionnements de MAPK3."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il MAPK3 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques."
}
},
{
"@type": "Question",
"name": "Des infections peuvent-elles affecter MAPK3 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent perturber la signalisation de MAPK3."
}
}
]
}
]
}
The Incident Commander (IC) decision-making process has previously been modeled primarily by qualitative evaluation methods, which has made it difficult to generalize an objective model. In this study...
Complex multimorbidity, defined either as three or more chronic conditions affecting three or more different body systems or by the patients General Practitioner (GPs), is associated with various adve...
To identify decision characteristics for which SDM authors deem SDM appropriate or not, and what arguments are used....
We applied two search strategies: we included SDM models from an earlier review (strategy 1) and conducted a new search in eight databases to include papers other than describing an SDM model, such as...
From the 92 included papers, we identified 18 decision characteristics for which authors deemed SDM appropriate, including preference-sensitive, equipoise and decisions where patient commitment is nee...
The findings of this review show the broad range of decision characteristics for which authors deem SDM appropriate, the ambiguity of some, and potential limits of SDM....
The findings can stimulate clinicians to (re)consider pursuing SDM in situations in which they did not before. Additionally, it can inform SDM campaigns and educational programs as it shows for which ...
People make oral healthcare decisions regardless of having partial information, misinformation, sources that deliberately mislead, or information that is culturally influenced. This is particularly tr...
The researchers used a grounded theory qualitative study design to explain data for a theory of OHDA. Participants from Appalachia, in 20-minute interviews, provided insights into concepts that influe...
Five overarching concepts that embody OHDA were discovered: Affect (Level of Pain/Emotion/Stress involvement), Awareness, Trust/belief, Resources, and Risk Perception. All participants discussed the i...
To influence a person's OHDA, public health officials and researchers need to address the person's affect, level of awareness, trust/belief, available resources, and risk perception. Social media is v...
People with Gambling Disorder (GD) often make risky decisions and experience cognitive distortions about gambling. Moreover, people with GD have been shown to be overly confident in their decisions, e...
We used data from our previous mixed-gamble study, in which participants were given the choice of a certain option or a 50/50 gamble with potential gains or losses, after which they rated their confid...
While HCs were more confident when making certain than risky choices, GD patients were specifically more confident when making risky choices than certain choices. Notably, relative to HCs, confidence ...
The current findings highlight the potential relevance of confidence and "regret" as cognitive mechanisms feeding into excessive risk-taking as seen in GD. Moreover, this study adds to the limited pre...
Pubertal development is a potential trigger for increases in risk-taking behaviours during adolescence. Here, we sought to investigate the relationship between puberty and neural activation during ris...
Self-control can be defined as making choices in accordance with long-term, rather than short-term, patterns of behavior. Rachlin (2016) suggested a novel technique to enhance self-control, by which i...
Patients with anorexia nervosa (AN) show impaired decision-making ability, but it is still unclear if this is a trait marker (i.e., being associated with AN at any stage of the disease) or a state par...
Ninety-one patients with acute AN (A-AN), 90 unaffected relatives (UR), 23 patients remitted from AN (R-AN), and 204 healthy controls (HC) carried out the Iowa gambling task (IGT). Prospective valence...
Patients with A-AN had lower performance at the IGT (...
Alteration of decision-making ability did not show endophenotypic features. Impaired decision-making seems a state-associated characteristic of AN, resulting from the interplay between trait-associate...
Although traditional medical ethics focuses on the dyadic doctor-patient relationship, when the patient is a child, the relationship is triadic, meaning it involves the patient, the parent(s), and the...
Despite advances in prevention, detection, and treatment, cardiovascular disease is a leading cause of mortality and represents a major health problem worldwide. Artificial intelligence and machine le...